Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.
Stocks · News reference
Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss narrowed; Game Your Game led gainers, Masonglory fell.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $34
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $27 to $34.
Adicet Bio shares are trading lower after the company announced safety and efficacy data from the Phase 1 study evaluating prulacabtagene leucel as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis.
8-K filing — Adicet Bio, Inc. (ACET)
Filed: 2026-09-28 AccNo: 0001720580-26-000060 Size: 15 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Gold Fields, Harmony Gold Mining, Anglogold Ashanti And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures fell as gold and silver prices slid, sending Gold Fields down 16% and other precious-metal stocks lower in premarket trading.
Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care
Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.